Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC, Energized By Androgel, Presses For Patent Settlement Ban

This article was originally published in The Pink Sheet Daily

Executive Summary

In the swirling alliances of the health care reform debate, a press conference by FTC and House Democrats features a consumer who feels he was harmed by the deal between Solvay and generic firms.

You may also be interested in...



FTC Rulemaking Could Be Next (And Last?) Attempt To Curb "Pay-For-Delay"

Potential Federal Trade Commission rule-making looms over the contentious issue of "pay -for-delay" in brand/generic settlements, particularly as the judicial and legislative environments remain uncertain.

FTC Rulemaking Could Be Next (And Last?) Attempt To Curb "Pay-For-Delay"

Potential Federal Trade Commission rule-making looms over the contentious issue of "pay -for-delay" in brand/generic settlements, particularly as the judicial and legislative environments remain uncertain.

Obama Health Reform Plan Uses MA Cuts, Pharma Fees To Close Donut Hole

The Obama administration's proposal on health care reform would phase out the Medicare Part D coverage gap and pay for it through cuts to Medicare Advantage plans and with annual fees on branded biopharmaceutical companies

Related Content

Topics

UsernamePublicRestriction

Register

PS070101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel